Institutional Perspectives in Neurology: Multiple Sclerosis

Cutting Edge Care in Multiple Sclerosis: Advances in S1P Therapy

July 28, 2021

Jessica L. Stulc, MD, MPH, offered an in-depth review of the latest approved therapies in the sphingosine phosphate 1 targeting class of oral medications for MS including ozanimod (Zeposia; BMS) and ponesimod (Ponvory; Janssen).